Article
Document
Information Content Entity
Academic Article
Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial.
RDF description of Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial. - http://irises.unisr.it/resource/item/8055
Generically Dependent Continuant